Adamis Pharmaceuticals logo
Adamis Appoints Vickie Reed to Board of Directors
May 26, 2022 16:05 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the appointment of Vickie Reed as a new director and member of the company’s board of...
PURA LOGO Update May 12.jpg
PURA Enters Strategic Discussions To Bolster Industrial Hemp Strategy
May 26, 2022 11:30 ET | Puration Inc.
Dallas, Texas, May 26, 2022 (GLOBE NEWSWIRE) -- Puration, Inc. (OTC Pink: PURA) today announced a plan to bolster the company’s industrial hemp development strategy. This week, the company entered...
Cellectis Logo.png
Cellectis’ Annual Shareholders’ General Meeting to be Held on June 28, 2022
May 23, 2022 16:35 ET | Cellectis Inc.
NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving...
Elevar Therapeutics Names Paul Friel Chief Commercial Officer, Michael Palucki VP of Manufacturing
May 23, 2022 10:15 ET | Elevar Therapeutics
SALT LAKE CITY, May 23, 2022 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who...
ibn-iw-globe-2.png
IBN (InvestorBrandNetwork) Announces Latest Episode of The Bell2Bell Podcast featuring Eric Weisblum, CEO of Silo Pharma Inc.
May 18, 2022 08:17 ET | InvestorBrandNetwork (IBN)
LOS ANGELES, May 18, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- IBN (InvestorBrandNetwork), a multifaceted communications organization engaged in connecting public companies to the investment...
Cellectis Logo.png
Cellectis Presents Research Data on a Novel Immune-Evasive Universal CAR T-cell at ASGCT
May 16, 2022 08:15 ET | Cellectis Inc.
NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Affimed Logo.jpg
Affimed Presents Data on Innate Cell Engagers AFM24 and AFM28 at 19th Meeting of the Society for Natural Immunity
May 16, 2022 08:00 ET | Affimed N.V.
Correlative science data from AFM24-101 clinical study support the rationale to develop AFM24 as monotherapy and in combination therapiesFirst preclinical data set on the combination of AFM28 with...
Affimed Logo.jpg
Affimed to Present Preclinical Data Demonstrating Cytotoxic Activity of its Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)
May 12, 2022 10:31 ET | Affimed N.V.
The novel bispecific innate cell engager AFM28 stimulates NK cells to destroy CD123-positive tumor cells via antibody-dependent cellular cytotoxicity.AFM28 induces effective lysis of hematological...
Cellectis Logo.png
Monthly information on share capital and company voting rights
May 10, 2022 16:43 ET | Cellectis Inc.
NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- Listing market: Euronext GrowthISIN code: FR0010425595 DateTotal number of shares in the capitalTotal number of voting...
Moonlake.png
MoonLake Immunotherapeutics announces the publication of new long-term disease control data from a Phase 2b Psoriasis trial of the Nanobody® sonelokimab
May 09, 2022 07:00 ET | MoonLake Immunotherapeutics
MoonLake Immunotherapeutics announces the publication of new long-term disease control data from a Phase 2b Psoriasis trial of the Nanobody® sonelokimab Higher rates of complete skin clearance were...